Pfizer Reports Positive Data From Phase 3 Trial Of Talzenna/

NEW YORK CITY (dpa-AFX) - Pfizer (PFE) Thursday reported positive results from the Phase 3 TALAPRO-2 study of Talzenna, an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with

Related Keywords

Dennis Riedl , Pfizer , Drug Administration , Priority Review , Reports , Positive , Data , Rom , Hase , Trial , Talzenna , Xtandi , Combo ,